CN107921106B - Wt1抗原肽和免疫调节剂的组合用途 - Google Patents

Wt1抗原肽和免疫调节剂的组合用途 Download PDF

Info

Publication number
CN107921106B
CN107921106B CN201680042322.XA CN201680042322A CN107921106B CN 107921106 B CN107921106 B CN 107921106B CN 201680042322 A CN201680042322 A CN 201680042322A CN 107921106 B CN107921106 B CN 107921106B
Authority
CN
China
Prior art keywords
cancer
peptide
seq
pharmaceutically acceptable
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680042322.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN107921106A (zh
Inventor
高须秀夫
中村惠弥
后藤正志
杉边奈津子
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
International Institute of Cancer Immunology Inc
Original Assignee
Sumitomo Pharmaceuticals Co Ltd
Sumitomo Dainippon Pharma Co Ltd
International Institute of Cancer Immunology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Pharmaceuticals Co Ltd, Sumitomo Dainippon Pharma Co Ltd, International Institute of Cancer Immunology Inc filed Critical Sumitomo Pharmaceuticals Co Ltd
Publication of CN107921106A publication Critical patent/CN107921106A/zh
Application granted granted Critical
Publication of CN107921106B publication Critical patent/CN107921106B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CN201680042322.XA 2015-05-20 2016-05-19 Wt1抗原肽和免疫调节剂的组合用途 Active CN107921106B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2015-103145 2015-05-20
JP2015103145 2015-05-20
PCT/JP2016/064923 WO2016186177A1 (ja) 2015-05-20 2016-05-19 Ｗｔ１抗原ペプチドおよび免疫調節剤の併用

Publications (2)

Publication Number Publication Date
CN107921106A CN107921106A (zh) 2018-04-17
CN107921106B true CN107921106B (zh) 2023-09-08

Family

ID=57320344

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680042322.XA Active CN107921106B (zh) 2015-05-20 2016-05-19 Wt1抗原肽和免疫调节剂的组合用途

Country Status (7)

Country Link
US (2) US20180140691A1 (https=)
EP (1) EP3299028B1 (https=)
JP (4) JP6515182B2 (https=)
CN (1) CN107921106B (https=)
CA (1) CA2986367A1 (https=)
ES (1) ES2993462T3 (https=)
WO (1) WO2016186177A1 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201507883SA (en) 2013-03-29 2015-10-29 Sumitomo Dainippon Pharma Co Ltd Wt1-antigen peptide conjugate vaccine
SMT202200370T1 (it) 2015-11-20 2022-11-18 Memorial Sloan Kettering Cancer Center Composizione per il trattamento del cancro
WO2018039629A2 (en) 2016-08-25 2018-03-01 Northwestern University Micellar spherical nucleic acids from thermoresponsive, traceless templates
US12383608B2 (en) 2016-11-30 2025-08-12 Sumitomo Pharma Co., Ltd. WT1 helper peptides and combinations of WT1 helper peptide and conjugate of cancer antigen peptides
ES2973548T3 (es) 2016-12-22 2024-06-20 Cue Biopharma Inc Polipéptidos multiméricos moduladores de linfocitos T y métodos para su uso
MY192920A (en) * 2017-03-15 2022-09-15 Cancer Res Malaysia Immunogenic peptide composition
US11696954B2 (en) 2017-04-28 2023-07-11 Exicure Operating Company Synthesis of spherical nucleic acids using lipophilic moieties
CN111051346A (zh) * 2017-05-31 2020-04-21 斯特库伯株式会社 使用免疫特异性结合btn1a1的抗体和分子治疗癌症的方法
BR112020003362A2 (pt) * 2017-08-28 2020-08-18 Bristol-Myers Squibb Company antagonistas de tim-3 para o tratamento e diagnóstico de cânceres
BR112020006677A2 (pt) * 2017-10-05 2020-10-06 Fulcrum Therapeutics, Inc. uso de inibidores p38 para reduzir a expressão de dux4
KR102184377B1 (ko) * 2018-02-19 2020-11-30 고려대학교 산학협력단 열충격단백질의 에피토프를 포함하는 백신 및 이의 용도
JP7162675B2 (ja) 2018-09-28 2022-10-28 住友ファーマ株式会社 注射用組成物
CA3115240A1 (en) 2018-10-05 2020-04-09 International Institute Of Cancer Immunology, Inc. Composition for preventing or treating benign tumor
MX2021012422A (es) * 2019-04-10 2022-01-19 Slsg Ltd Llc Composición de inmunoterapia multivalente y métodos para usarse en el tratamiento de cánceres positivos a la proteína del tumor de wilms 1 (wt1).
WO2021021924A1 (en) * 2019-07-29 2021-02-04 Huang Cai Gu Formulation of antibody based drugs for treating lung cancer by inhalation
CN114945383A (zh) 2019-12-10 2022-08-26 住友制药株式会社 肽乳液制剂的调制方法
AU2020414355A1 (en) * 2019-12-24 2022-08-11 Neoleukin Therapeutics, Inc. Combination therapy using an IL-2 receptor agonist and an immune checkpoint inhibitor
WO2021231405A1 (en) * 2020-05-12 2021-11-18 Board Of Regents, The University Of Texas System Methods for treating glioblastoma
WO2021231376A2 (en) 2020-05-12 2021-11-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
WO2021230638A1 (en) * 2020-05-12 2021-11-18 Lg Chem, Ltd. Multimeric t-cell modulatory polypeptides and methods of use thereof
JP7153287B2 (ja) * 2020-05-12 2022-10-14 住友ファーマ株式会社 癌を処置するための医薬組成物
CN111647066B (zh) * 2020-07-01 2020-12-18 维肽瀛(上海)生物技术有限公司 Wt1多肽肿瘤抑制剂
US20240024444A1 (en) * 2020-08-07 2024-01-25 Medrx Co., Ltd. Combined Preparation
BR112023019492A2 (pt) * 2021-03-31 2023-10-31 Celleron Therapeutics Ltd Composto ou um sal ou solvato farmaceuticamente aceitável do mesmo, métodos para tratar ou prevenir uma doença, distúrbio ou condição, para potencializar uma resposta imunológica, para potencializar o efeito de uma vacina, para sensibilizar o sistema imunológico de um indivíduo, para potencializar a resposta imunológica a uma vacina em um indivíduo e para prevenir ou tratar uma doença, distúrbio ou condição, usos do composto ou um sal farmaceuticamente aceitável do mesmo e de uma combinação, combinação, produto farmacêutico, e, composição farmacêutica
CN117838860B (zh) * 2023-11-27 2025-03-14 四川大学 一种抑制周围神经侵袭的药物、药物组合物、联合用药物
CN120463819B (zh) * 2024-11-18 2026-01-27 北京宝易生物技术有限公司 疫苗稀释液制备方法和应用
CN121015864B (zh) * 2025-10-31 2026-02-03 可蓝赛生物医药(上海)有限公司 一种含有多糖佐剂的肿瘤疫苗及其应用

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007130493A2 (en) * 2006-05-03 2007-11-15 Regents Of The University Of Colorado Cd40 agonist antibody/type1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity
WO2008051424A2 (en) * 2006-10-20 2008-05-02 University Of Southampton Human immune therapies using a cd27 agonist alone or in combination with other immune modulators
WO2010063011A2 (en) * 2008-11-28 2010-06-03 Emory University Methods for the treatment of infections and tumors
WO2011130434A3 (en) * 2010-04-13 2012-03-08 Celldex Therapeutics Inc. Antibodies that bind human cd27 and uses thereof
CN103157108A (zh) * 2011-12-13 2013-06-19 宁云山 免疫调节剂组合物及其药物组合物和应用
CN103830211A (zh) * 2012-11-27 2014-06-04 上海曼克尔瑞生物医药技术有限公司 一种β-catenin蛋白抑制剂-姜黄素在肝癌治疗方面的应用
CN103961702A (zh) * 2013-02-05 2014-08-06 日东电工株式会社 粘膜给予用wt1肽癌症疫苗组合物
WO2014134165A1 (en) * 2013-02-26 2014-09-04 Memorial Sloan-Kettering Cancer Center Compositions and methods for immunotherapy
WO2014157692A1 (ja) * 2013-03-29 2014-10-02 大日本住友製薬株式会社 Ｗｔ１抗原ペプチドコンジュゲートワクチン

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2572714A1 (en) * 2002-12-30 2013-03-27 3M Innovative Properties Company Immunostimulatory Combinations
ES2332590T3 (es) * 2003-01-15 2010-02-09 International Institute Of Cancer Immunology, Inc. Dimero peptidico.
US7714139B2 (en) * 2003-03-27 2010-05-11 Lankenau Institute For Medcial Research IDO inhibitors and methods of use
US20040197312A1 (en) * 2003-04-02 2004-10-07 Marina Moskalenko Cytokine-expressing cellular vaccine combinations
RU2375076C2 (ru) * 2003-07-10 2009-12-10 Цитос Биотехнологи Аг Укомплектованные вирусоподобные частицы
EP1670513B1 (en) * 2003-10-06 2013-01-23 Cedars-Sinai Medical Center Cox-2 inhibitors and dendritic cells for use in the treatment of cancer.
JP5427027B2 (ja) * 2006-05-03 2014-02-26 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・コロラド，ア・ボディー・コーポレイト Ｃｄ４０アゴニスト抗体／ｉ型インターフェロン相乗性アジュバントの結合体、それを含む複合体、および細胞性免疫を強化する治療としてのその使用
KR101208587B1 (ko) * 2009-06-24 2012-12-06 여오영 하이드록시클로로퀸을 포함하는 항암 치료를 위한 국소 투여용 주사제 조성물
CA2858876A1 (en) * 2011-12-15 2013-06-20 The University Of Chicago Methods and compositions for cancer therapy using mutant light molecules with increased affinity to receptors
AR090263A1 (es) * 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
CA2920377A1 (en) * 2013-08-05 2015-02-12 Cambridge Enterprise Limited Inhibition of cxcr4 signaling in cancer immunotherapy

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007130493A2 (en) * 2006-05-03 2007-11-15 Regents Of The University Of Colorado Cd40 agonist antibody/type1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity
WO2008051424A2 (en) * 2006-10-20 2008-05-02 University Of Southampton Human immune therapies using a cd27 agonist alone or in combination with other immune modulators
WO2010063011A2 (en) * 2008-11-28 2010-06-03 Emory University Methods for the treatment of infections and tumors
WO2011130434A3 (en) * 2010-04-13 2012-03-08 Celldex Therapeutics Inc. Antibodies that bind human cd27 and uses thereof
CN103157108A (zh) * 2011-12-13 2013-06-19 宁云山 免疫调节剂组合物及其药物组合物和应用
CN103830211A (zh) * 2012-11-27 2014-06-04 上海曼克尔瑞生物医药技术有限公司 一种β-catenin蛋白抑制剂-姜黄素在肝癌治疗方面的应用
CN103961702A (zh) * 2013-02-05 2014-08-06 日东电工株式会社 粘膜给予用wt1肽癌症疫苗组合物
WO2014134165A1 (en) * 2013-02-26 2014-09-04 Memorial Sloan-Kettering Cancer Center Compositions and methods for immunotherapy
WO2014157692A1 (ja) * 2013-03-29 2014-10-02 大日本住友製薬株式会社 Ｗｔ１抗原ペプチドコンジュゲートワクチン

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
β-连环蛋白与大肠癌关系的研究进展;杨平玲等;《实用医学杂志》;20080425(第08期);全文 *

Also Published As

Publication number Publication date
JP6956967B2 (ja) 2021-11-02
HK1250213A1 (en) 2018-12-07
US20180140691A1 (en) 2018-05-24
JPWO2016186177A1 (ja) 2018-04-12
ES2993462T3 (en) 2024-12-30
EP3299028A1 (en) 2018-03-28
JP6713160B2 (ja) 2020-06-24
JP2020075934A (ja) 2020-05-21
CA2986367A1 (en) 2016-11-24
JP2022000454A (ja) 2022-01-04
CN107921106A (zh) 2018-04-17
JP7253210B2 (ja) 2023-04-06
JP6515182B2 (ja) 2019-05-15
EP3299028A4 (en) 2019-02-27
WO2016186177A1 (ja) 2016-11-24
JP2019135251A (ja) 2019-08-15
US20240293521A1 (en) 2024-09-05
HK1248546A1 (zh) 2018-10-19
EP3299028B1 (en) 2024-10-30

Similar Documents

Publication Publication Date Title
CN107921106B (zh) Wt1抗原肽和免疫调节剂的组合用途
JP7209986B2 (ja) 癌を処置するための医薬組成物
WO2018181648A1 (ja) Ｗｔ１癌抗原ペプチドおよびこれを含むペプチドコンジュゲート体
JP7209963B2 (ja) Ｗｔ１ヘルパーペプチド及びこれと癌抗原ペプチドコンジュゲート体との組合せ
WO2019131722A1 (ja) Ｗｔ１由来ペプチドのコンジュゲート体およびこれを含む組成物
HK1248546B (zh) Wt1抗原肽和免疫调节剂的组合用途
HK40084495A (en) Pharmaceutical composition for treating cancer
HK1250213B (en) Combination of wt1 antigen peptide, immunomodulator and wt1 helper peptide
HK40032856A (en) Conjugate of wt1-derived peptides and composition comprising the same

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1248546

Country of ref document: HK

CB02 Change of applicant information
CB02 Change of applicant information

Address after: Osaka City, Osaka of Japan

Applicant after: SUMITOMO PHARMACEUTICALS CO.,LTD.

Applicant after: International Institute of Cancer Immunology, Inc.

Address before: Osaka City, Osaka of Japan

Applicant before: Dainippon Sumitomo Pharma Co.,Ltd.

Applicant before: International Institute of Cancer Immunology, Inc.

CB02 Change of applicant information

Address after: No. 6-8, Doshucho 2-chome, Chuo-ku, Osaka City, Osaka Prefecture, Japan

Applicant after: SUMITOMO PHARMACEUTICALS CO.,LTD.

Applicant after: International Institute of Cancer Immunology, Inc.

Address before: Osaka City, Osaka of Japan

Applicant before: SUMITOMO PHARMACEUTICALS CO.,LTD.

Applicant before: International Institute of Cancer Immunology, Inc.

CB02 Change of applicant information
GR01 Patent grant
GR01 Patent grant
TG01 Patent term adjustment

Free format text: NEW EXPIRY DATE: 20370520

TG01 Patent term adjustment
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20250918

Address after: Japan Osaka suita

Patentee after: International Institute of Cancer Immunology, Inc.

Country or region after: Japan

Address before: 6-8 Daoxiu cho 2-chome, Chuo ku, Osaka City, Osaka Prefecture, Japan

Patentee before: SUMITOMO PHARMACEUTICALS CO.,LTD.

Country or region before: Japan

Patentee before: International Institute of Cancer Immunology, Inc.